文献速递乳腺癌支持与姑息治疗

生物类似药在肿瘤学中的经济影响与治疗创新

Biosimilars in oncology: Effects on economy and therapeutic innovations.
PubMed 文献 · Eur J Cancer · 2020-09-17

该研究基于德国医疗系统,以曲妥珠单抗(乳腺癌)、利妥昔单抗(滤泡性淋巴瘤)和G-CSF(支持治疗)为例,模拟生物类似药替代原研药的年度节省潜力。结果显示,应用生物类似药可产生显著年度节省,尤其在高发病率或长期维持治疗中。

要点

  • 生物类似药可大幅降低肿瘤治疗总费用。
  • 利妥昔单抗、非格司亭、培非格司亭和曲妥珠单抗均显示节省潜力。
  • 节省资源可用于抵消创新疗法的融资需求。

核心结论

  • 持续使用生物类似药可显著降低总体治疗费用,尤其对费用高昂的长期维持治疗和高发病率疗法。
  • 若充分利用生物类似药,可释放大量医疗系统资源以抵消新创新疗法的融资。

研究设计与样本

  • 基于已有卫生经济学分析,对德国医疗系统进行真实世界模拟。
  • 针对曲妥珠单抗(乳腺癌)、利妥昔单抗(滤泡性淋巴瘤)和G-CSF(支持治疗)计算生物类似药与原研药的处方及成本控制潜力。
  • 发病率计算基于罗伯特·科赫研究所、慕尼黑癌症登记处及认证中心质量指标等数据。
  • 成本计算基于Lauer-Taxe®(药品价格信息官方参考)。

主要发现

  • 利妥昔单抗用于滤泡性淋巴瘤的年节省潜力可达4.9百万欧元。
  • 非格司亭的年节省潜力为40.5百万欧元。
  • 培非格司亭的年节省潜力为56.4百万欧元。
  • 曲妥珠单抗的年节省潜力在95.9至120.5百万欧元之间。

临床怎么用

  • 在成本敏感且长期维持治疗的肿瘤场景中优先考虑生物类似药。
  • 在高发病率肿瘤治疗中充分利用生物类似药以释放资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The introduction of new and innovative treatment options for cancer patients is accompanied by a tremendous increase in healthcare costs. Consequently, new financing approaches are strongly needed to reduce the burden on the healthcare system. The introduction of biosimilars - biological drugs containing the active substance of an already approved reference biological drug - can potentially relieve the burden on healthcare systems. Calculating the costs for three frequently used biosimilars, we simulated the health-economic impact of biosimilars in the real world for the German healthcare system. METHODS: Based on available health-economic analyses, the actual prescription and cost containment potential of biosimilars compared to the originator were calculated exemplarily for the cost-intensive therapies trastuzumab in breast cancer, rituximab in follicular lymphoma and G-CSF in supportive care. Incidence calculations were based e.g. on data from the Robert-Koch-Institution, Munich Cancer Registry, and quality indicators of certified centres. Cost calculation was based on Lauer-Taxe® (official reference for pharmaceutical price information). RESULTS: The application of biosimilars would generate potential annual savings for the chosen examples of up to 4.9 Mio EUR for rituximab in follicular lymphoma, 40.5 Mio EUR for filgrastim, 56.4 Mio EUR for pegfilgrastim, and between 95.9 and 120.5 Mio EUR for trastuzumab. CONCLUSIONS: The consequent use of biosimilars allows a considerable reduction of overall treatment costs, especially for cost-intensive long-term maintenance treatments and therapies with high incidences. If the option of biosimilar usage is fully exploited, enormous resources could be released within the healthcare system in order to offset financing new innovative therapies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hübel K, Kron F, Lux MP, et al. Biosimilars in oncology: Effects on economy and therapeutic innovations. Eur J Cancer. 2020. PMID: 32950935. doi:10.1016/j.ejca.2020.07.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。